Nova’s non small cell lung cancer (NSCLC) disease model of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LUAD) includes intracellular signaling pathways, tumor cell dynamics with the immune system and tumor (including metastases) evolution. It allows investigating new treatments against EGFR mutant LUAD.


  1. Model description (NSCLC)
    1. Biological submodels
    2. Drugs that can be tested
    3. Populations of interest
    4. Possible clinical endpoints
  2. Early insights to optimize your trial design

    1. Drug regimen
    2. Combination of treatments
    3. Patient selection


Get your questions answered by downloading the free pdf and learn more about your therapeutic area of interest!

  • Your information will be processed by Nova to send you the content requested. For more information about our processing or to exercise your GDPR rights, see our Privacy Policy
  • This field is for validation purposes and should be left unchanged.